

GENFIT UNVEILS ITS THERANOSTIC STRATEGY

The BMGFT01/02 and BMGFT03 biomarker programs developed in the field of cardiometabolic and neurodegenerative diseases are based on a breakthrough technology.

Pharmaceutical collaboration discussions have been initiated to provide pharmaceutical laboratories with optimized companion diagnostic tests allowing to rapid patient assessment and response to new therapies.

Lille (France), Cambridge (Massachusetts, United States), February 24, 2009 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today unveiled its theranostic strategy. GENFIT has made significant progress in developing an innovative biomarker technology providing a fast, focused and predictive response of the effectiveness of new treatments dedicated to certain metabolic and neurodegenerative diseases.

The BMGFT01 program is dedicated to early detection of atherosclerosis and is the most advanced program enabling the study of atherosclerotic plaque formation and its evolution in a non-invasive manner. The BMGFT03 program focuses more on neurodegenerative diseases including Alzheimer's disease.

The development of these blood markers is based on a breakthrough technology on which the Company intends to invest in order to offer its collaborators a companion test that could be incorporated into their R&D strategy and adapted to their most advanced drug candidates' needs.

The BMGFT01 program could reach clinical proof of concept in the coming months offering a significant added value to pharmaceutical companies. As part of a translational research strategy, these new markers represent a helpful tool for strategic decision-making to optimize clinical development of drug candidates. Such approaches have become increasingly more important within the pharmaceutical industry.

Jean-François Mouney, Chairman of the Management Board of GENFIT, announced: "Our research collaborations with the pharmaceutical industry along with the recommendations of European and North American public authorities have convinced us of the benefits of investing in this approach. In the near term, these new tools will enhance the intrinsic value of our drug discovery engine along with our drug candidates. We envision these new programs not only provide additional benefits to our existing industrial alliances, but also strengthen our ability to forge new alliances with other pharmaceutical leaders. We are currently seeking partnership opportunities to further optimize this technology with companies involved in diagnostic in the field of atherosclerosis as well as in other indications."

About GENFIT:

A biopharmaceutical company, GENFIT studies the regulation and function of genes implicated in many of the most widespread diseases. GENFIT's scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT's programs, conducted in partnership with pharmaceutical companies which include SANOFI-AVENTIS, SOLVAY GROUP, PIERRE FABRE, MERCK AG, and SERVIER, treat the most prevalent metabolic diseases. GENFIT's development of proprietary drugs focuses on early diagnosis, prevention and treatment of micro and macro-vascular diseases in pre-diabetes and diabetes. GENFIT is also committed in research programmes in specific neurodegenerative diseases. GENFIT possesses a rich and diversified pipeline of drug candidates at different stages of development – development carried out by GENFIT alone or in partnership. GENFIT's lead proprietary compound, GFT505, is currently in Phase II and another compound in partnership with SANOFI-AVENTIS (AVE0897) is now completing Phase I. With facilities in Lille, France, and Cambridge, MA (USA), the company has over 130 employees on staff, including over 100 scientists. GENFIT is a public company listed on the Alternext by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney - Chairman of the Management Board
+ 33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 - milestones@milestones-fr.com

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.